Sulaquin, Gina F.
HRN: 21-53-30 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
07/10/2022
CEFTRIAXONE 1G (VIAL)
07/10/2022
07/16/2022
IV DRIP
95mg
Q12
T/c Pertussis, Cannot Totally Rule Out Cardiac Pathology
Waiting Final Action
Indication: Empiric Type of Infection: PneumoniaURTICardiovascular Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes